홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.1
  1. 홈
  2. /화합물

케토프로펜

Ketoprofen

HCID 3825
새 반응
인쇄

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
22071-15-4
표준 SMILES
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1
InChIKey
DKYWVDODHFEZIM-UHFFFAOYSA-N
분자식
C16H14O3
평균 분자량
254.28 g/mol
단동위원소 질량
254.09429431

개요

Ketoprofen is an oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2. It has a role as a non-steroidal anti-inflammatory drug, an antipyretic, an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor, a xenobiotic, an environmental contaminant and a drug allergen. It is a member of benzophenones and an oxo monocarboxylic acid. It is functionally related to a propionic acid.

이름 및 식별자

우선 이름
Ketoprofen
IUPAC
2-(3-benzoylphenyl)propanoic acid
현지명
케토프로펜
영어명
Ketoprofen
분자식
C16H14O3
분자량
254.28

이름 및 동의어

ketoprofen22071-15-42-(3-Benzoylphenyl)propanoic acid2-(3-Benzoylphenyl)propionic acidOrudisCapistenActronOruvailAlrheumatKetoprofeneAneolm-Benzoylhydratropic acid
이름 더 보기
케토프로펜케토프로펜(KETOPROFEN)ProfenidKETOPROFEN USP2-(3-benzoylphenyl)-propionicaci(2RS)-2-(3-Benzoylphenyl)propanoic acid
3-Benzoylhydratropic acidIso-KKetoprofenoOrudis KTRP-19583SectorKetoprofenumKetorin

데이터베이스 식별자

CAS
22071-15-4
PubChem CID
3825
DTXSID
DTXSID6020771
ChEMBL
CHEMBL571
ChEBI
CHEBI:6128
UNII
90Y4QC304K
EC Number
244-759-8
Nikkaji
J3.468A

물성

구조 계산 물성보충 중

XLogP
3.1
극성 표면적
54.4 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
3
회전 가능 결합 수
4
무거운 원자 수
19
형식 전하
0
복잡도
331

실험 및 물리화학적 성질

Drugs · 4건

DEA NFLIS-Drug Category -> Analgesics

Pharmaceuticals -> NSAIDs

Pharmaceutical

Pharmaceuticals

LogP · 2건

3.2

3.12

Solubility2.13e-02 g/L
Human Drugs · 3건

Breast Feeding; Lactation; Milk, Human; Analgesic Agents; Anti-inflammatory Agents, Nonsteroidal

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Animal Drugs · 3건

Active Ingredients (Ketoprofen) -> FDA Greenbook

Pharmaceuticals -> Animal Drugs -> Approved in Taiwan

Pharmaceuticals -> UK Veterinary Medicines Directorate List

Melting Point94 °C
Physical DescriptionSolid
Dissociation Constants · 4건

3.98

4

3.8

4.45

Collision Cross Section · 4건

155.4 Ų [M+H]+ [CCS Type: TW]

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 5건

This chemical does not meet GHS hazard criteria for 0.1% (1 of 672) of reports.

Danger

H301 (99.7%): Toxic if swallowed [Danger Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P280, P301+P316, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 672 reports by companies from 29 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Regulatory Information · 2건

Status: Active Update: 30-06-2020 https://echa.europa.eu/registration-dossier/-/registered-dossier/24605

Ketoprofen: Does not have an individual approval but may be used under an appropriate group standard

Other Safety InformationIMAP assessments - Benzeneacetic acid, 3-benzoyl-.alpha.-methyl-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 3 (99.7%)

독성 정보

Hepatotoxicity · 1건

Prospective studies show that 1% to 2% of patients taking ketoprofen experience at least transient serum aminotransferase elevations. These may resolve even with drug continuation. Marked aminotransferase elevations (>3 fold elevated) occur in

Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Ketoprofen

vLess-DILI-concern

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

화학 및 산업

약리 정보

ATC Code · 5건

M02AA10

M - Musculo-skeletal system

M - Musculo-skeletal system

QM - Musculo-skeletal system

QM - Musculo-skeletal system

Protein Binding99% bound, primarily to albumin
Pharmacodynamics · 1건

Ketoprofen is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. Ketoprofen has pharmacologic actions similar to those of other prototypical NSAIDs, which inhibit prostaglandin synthesis. Ketoprofen is used to treat rheumatoid arthritis, osteoarthritis, dysmenorrhea, and alleviate moderate pain.

Mechanism of Action · 1건

The anti-inflammatory effects of ketoprofen are believed to be due to inhibition cylooxygenase-2 (COX-2), an enzyme involved in prostaglandin synthesis via the arachidonic acid pathway. This results in decreased levels of prostaglandins that mediate pain, fever and inflammation. Ketoprofen is a non-specific cyclooxygenase inhibitor and inhibition of COX-1 is thought to confer some of its side effects, such as GI upset and ulceration. Ketoprofen is thought to have anti-bradykinin activity, as well as lysosomal membrane-stabilizing action. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation.

Biological Half-LifeConventional capsules: 1.1-4 hours <p>Extended release capsules: 5.4 hours due to delayed absorption (intrinsic clearance is same as conventional capsules)</p>
Metabolism/Metabolites · 2건

Rapidly and extensively metabolized in the liver, primarily via conjugation to glucuronic acid. No active metabolites have been identified.

Ketoprofen has known human metabolites that include Ketoprofen glucuronide.

FDA Pharmacological Classification · 6건

90Y4QC304K

KETOPROFEN

Mechanisms of Action [MoA] - Cyclooxygenase Inhibitors

관련 반응

54건
반응 기록 만들기
HRID 163579 반응식
HRID 163579생성물로Training data from https://doi.org/10.1039/C8SC04228D (9/10)
HRID 179402 반응식
HRID 179402반응물로Training data from https://doi.org/10.1039/C8SC04228D (6/10)
HRID 371111 반응식
HRID 371111반응물로uspto-grants-1985_07
HRID 373356 반응식
HRID 373356반응물로uspto-grants-1992_11
HRID 478092 반응식
HRID 478092생성물로uspto-grants-1989_12
HRID 597796 반응식
HRID 597796반응물로uspto-grants-2011_03
HRID 620971 반응식
HRID 620971생성물로uspto-grants-1989_04
HRID 620972 반응식
HRID 620972생성물로uspto-grants-1989_04
이전1 / 7 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트

157.5 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

148.63 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

165.87 Ų [M+Na]+

물리화학적 성질

녹는점
93 · 93-96°C
끓는 점
357.5 °C · 357.5°C (rough estimate)
밀도
1.1565 · 1.1565 (rough estimate)
굴절률
1.56 · 1.5600 (estimate)
저장 조건
2 · 2-8°C
용해도
클로로포름과 메탄올에 약간 용해됩니다.
산도 계수 (pKa)
5.94 · pKa 5.94(MeOH/H2O) (Uncertain)
물리적 상태
고체
색상
흰색에서 황백색까지
생물학적 소스
synthetic
수용성
209 mg/L · 209mg/L(상온)
Merck
14 · 14,5305
주요 응용
법의학 및 독성학의약품(소분자)
InChI
1S/C16H14O3/c1-11(16(18)19)13-8-5-9-14(10-13)15(17)12-6-3-2-4-7-12/h2-11H,1H3,(H,18,19)
InChIKey
DKYWVDODHFEZIM-UHFFFAOYSA-N
SMILES
CC(C(O)=O)c1cccc(c1)C(=O)c2ccccc2
NIST
Ketoprofen(22071-15-4)
EPA
3 · Benzeneacetic acid, 3-benzoyl-.alpha.-methyl- (22071-15-4)

화학적 성질

White Crystalline Solid

Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation

안전 데이터

wgk
3
tsca
TSCA listed
rtecs
UE7570000
ridadr
2811
독성
LD50 orally in rats: 101 mg/kg (Ueno)
HS 번호
29183000
risk_code
25-36/37/38-23/24/25
hazard_code
T
safety_code
26-45-36/37/39
포장분류
III
위험 등급
6.1(b)
기존화학 물질
KE-02767
Hazard Classifications
Acute Tox. 3 OralAquatic Acute 1Eye Irrit. 2Skin Irrit. 2
스토리지 클래스
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects

Chemical Structure [CS] - Anti-Inflammatory Agents, Non-Steroidal

Established Pharmacologic Class [EPC] - Nonsteroidal Anti-inflammatory Drug

Ketoprofen is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of ketoprofen is as a Cyclooxygenase Inhibitor.

MeSH Pharmacological Classification · 2건

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes.

Absorption, Distribution and Excretion · 3건

Ketoprofen is rapidly and well-absorbed orally, with peak plasma levels occurring within 0.5 to 2 hours.

In a 24 hour period, approximately 80% of an administered dose of ketoprofen is excreted in the urine, primarily as the glucuronide metabolite.

Oral-dose cl=6.9 +/- 0.8 L/h [Ketoprofen Immediate-release capsules (4 × 50 mg)]

Cellular LocationsCytoplasm
Metabolite PathwaysKetoprofen Action Pathway

용도 및 제조

UsesUse (kg) in Switzerland (2009): >250
Use Classification · 2건

Animal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients

Pharmaceuticals -> Animal Drugs -> Approved in Taiwan

General Manufacturing InformationBenzeneacetic acid, 3-benzoyl-.alpha.-methyl-: INACTIVE
응용 분야 · 2건

용도Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties.

일반 설명Ketoprofen (Orudis, Rhodis) and suprofen (Profenal) areclosely related to fenoprofen in their structures, properties,and indications. Even though ketoprofen has been approvedfor OTC use (Orudis KT, Actron), its GI side effects aresimilar to indomethacin, and therefore its useshould be closely monitored, especially in patients with GIor renal problems.

상·하류 제품 정보

상류 원료

황산요오드 메탄3-벤조일페닐아세토니트릴나트륨에틸알코올3-벤조일페닐아세트산

하류 제품

프탈이드3-Acetylbenzoic acid

추가 설명

정의ChEBI: An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.